



BETA DRUGS LIMITED

BDL/PKL/SEC/2020
7th May, 2020

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400051

Subject: SYMBOL: BETA

Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations 2015 for the half year ended 31st March, 2020.

Dear Sir, / Madam,

With reference to the captioned subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(8) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March, 2020.

This is for your information and necessary records.

Thanking you,
Yours faithfully,
For Beta Drugs limited


Rajni Brar
Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Export & Mktd Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com
www.adleylab.com

E-Mail :- info@betadrugslimited.com
sales@adleylab.com

Statement of Deviation / Variation in utilisation of funds raised	
Name of listed entity	BETA DRUGS LIMITED
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others
Date of Raising Funds	10 th October, 2017
Amount Raised	Rs 1951.60 lakhs
Report filed for the half year ended	31 st March, 2020
Monitoring Agency	applicable / not applicable
Monitoring Agency Name, if applicable	-----
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Noted
Comments of the auditors, if any	None
Objects for which funds have been raised and where there has been a deviation, in the following table	There are no deviation

Original Object	Modified Object, if any	Original Allocation (Rs in lakhs)	Modified allocation, if any	Funds Utilised (Rs in lakhs)	Amount of Deviation/Variation for the half year according to applicable object	Remarks if any
Purchase of new plant & machinery and up gradation of our existing plant & machinery, civil construction work at existing manufacturing unit, To obtain registration of European union GMP & Pharmaceutical Inspection co-operation scheme, working capital & general corporate purpose	NA	1951.60	NA	1951.60	NIL	None

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

Rajni
Company Secretary
ACS - 24384

Name of Signatory: RAJNI BRAR
Designation: COMPANY SECRETARY

*Securities of our Company is listed on SME Platform i.e. NSE Emerge, hence statement of deviation and variation under regulation 32 of SEBI (LODR), 2015 is to be filed on half yearly basis.

Statement of Deviation / Variation in utilisation of funds raised	
Name of listed entity	BETA DRUGS LIMITED
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others
Date of Raising Funds	1 st May, 2019
Amount Raised	Rs 5,87,17,204.00
Report filed for the half year ended	31 st March, 2020
Monitoring Agency	applicable / not applicable
Monitoring Agency Name, if applicable	-----
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Noted
Comments of the auditors, if any	None
Objects for which funds have been raised and where there has been a deviation, in the following table	There are no deviation

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the half year according to applicable object	Remarks if any
The proceeds of the preferential allotment is to be utilised for (i) working capital requirements; (ii) for acquisition of shares of Adley Lab Limited, a promoter owned company engaged in manufacturing & supplying of API to Beta Drugs Limited & Adley Formulations Pvt Ltd.(a wholly owned subsidiary of Beta Drugs Limited) which will help Beta Drugs to accelerate its share as India's leading manufacturer of Oncology drugs.	NA	5,87,17,204	NA	5,87,17,204	NIL	None

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

Beta Drugs Limited


Company Secretary
ACS - 24584

Name of Signatory: RAJNI BRAR

Designation: COMPANY SECRETARY

*Securities of our Company is listed on SME Platform i.e. NSE Emerge, hence statement of deviation and variation under regulation 32 of SEBI (LODR), 2015 is to be filed on half yearly basis.